TC
AEGR

TFS Capital’s Aegerion Pharmaceuticals AEGR Stock Holding History

TFS Capital’s Portfolio AEGR Stock Details AEGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-38,771
Closed -$143K – 1348
2016
Q1 		$143K Sell
38,771
-335,820
-90% -$2.08M 0.02% 831
2015
Q4 		$3.78M Buy
374,591
+189,644
+103% +$2.28M 0.41% 50
2015
Q3 		$2.52M Buy
184,947
+153,996
+498% +$2.74M 0.24% 111
2015
Q2 		$587K Buy
+30,951
New +$670K 0.06% 475
2015
Q1 		– Sell
-27,750
Closed -$581K – 1262
2014
Q4 		$581K Buy
+27,750
New +$699K 0.06% 541
2014
Q3 		– Sell
-102,410
Closed -$3.29M – 1365
2014
Q2 		$3.29M Buy
102,410
+21,091
+26% +$785K 0.26% 86
2014
Q1 		$3.75M Sell
81,319
-26,096
-24% -$1.53M 0.25% 96
2013
Q4 		$7.62M Buy
+107,415
New +$8.21M 0.36% 31

Other funds holding AEGR

SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
JG
Jefferies Group New York $12B AUM 6.2% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

TFS Capital's AEGR Position: Q2 2016 in Review

TFS Capital sold out of Aegerion Pharmaceuticals (AEGR) in Q2 2016, closing a stake of 38,771 shares — an estimated $143K sold.

TFS Capital first reported a position in AEGR in Q4 2013 and held it in 8 quarters. The position peaked at $7.62M in Q4 2013. 71 funds tracked by Wall St. Rank hold AEGR as of Q2 2016.

  • TFS Capital reported no remaining Aegerion Pharmaceuticals position as of Q2 2016 after selling out during the quarter.
  • TFS Capital sold 38,771 Aegerion Pharmaceuticals shares in Q2 2016, an estimated $143K.
  • TFS Capital first reported a position in Aegerion Pharmaceuticals in Q4 2013 and held it in 8 quarters.
  • TFS Capital's Aegerion Pharmaceuticals position peaked at $7.62M in Q4 2013.
  • 71 funds tracked by Wall St. Rank held Aegerion Pharmaceuticals as of Q2 2016.

Based on TFS Capital's 13F filing for Q2 2016, filed 11 Aug 2016.